Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells

被引:20
作者
Kyratzi, Elli
Pavlaki, Maria
Kontostavlaki, Dimitra
Rideout, Hardy J.
Stefanis, Leonidas [1 ]
机构
[1] Acad Athens, Fdn Biomed Res, Div Basic Neurosci, Athens, Greece
[2] Columbia Univ, Dept Neurol, New York, NY USA
关键词
apoptosis; caspase; Parkin; Parkinson's disease; proteasomal activity;
D O I
10.1111/j.1471-4159.2007.04620.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in Parkin, an E3 ligase, which participates in the ubiquitin-proteasome system (UPS), cause juvenile onset Parkinson's disease (PD). Some mutants aggregate upon over-expression, but the effects of such aggregation on the UPS and neuronal survival have not been characterized. We show in this study that transient over-expression of wild type (WT) Parkin or various mutants in human neuroblastoma cells leads to localized accumulation of green fluorescent protein (GFP(u)), an artificial proteasomal substrate, indicative of UPS dysfunction. Parkin mutants, but not WT, aggregated, and GFP(u) and ubiquitin accumulated within such aggregates. Apoptotic death occurred only with mutant Parkin overexpression, and correlated with aggregation, but not GFPu accumulation. Enzymatic proteasomal activity was slightly increased with WT Parkin and decreased with mutant Parkin over-expression. This decrease was, at least in part, due to caspase activation. We conclude that mutant forms of Parkin can exert toxic effects on neuronal cells, possibly through their propensity to aggregate. Both WT and mutant forms can induce localized UPS dysfunction, likely through different mechanisms. This raises a note of caution regarding forced over-expression of Parkin as a neuroprotective strategy in PD or other neurodegenerative conditions and suggests a possible toxic gain of function for certain mutant forms of Parkin.
引用
收藏
页码:1292 / 1303
页数:12
相关论文
共 35 条
[1]   Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin [J].
Ardley, HC ;
Scott, GB ;
Rose, SA ;
Tan, NGS ;
Markham, AF ;
Robinson, PA .
MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (11) :4541-4556
[2]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[3]   Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis [J].
Canu, N ;
Barbato, C ;
Ciotti, MT ;
Serafino, A ;
Dus, L ;
Calissano, P .
JOURNAL OF NEUROSCIENCE, 2000, 20 (02) :589-599
[4]   The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg [J].
Ciechanover, A ;
Brundin, P .
NEURON, 2003, 40 (02) :427-446
[5]   RING finger 1 mutations in Parkin produce altered localization of the protein [J].
Cookson, MR ;
Lockhart, PJ ;
O'Farrell, C ;
Schlossmacher, M ;
Farrer, MJ .
HUMAN MOLECULAR GENETICS, 2003, 12 (22) :2957-2965
[6]   Parkin interacts with the proteasome subunit α4 [J].
Dächsel, JC ;
Lücking, CB ;
Deeg, S ;
Schultz, E ;
Lalowski, M ;
Casademunt, E ;
Corti, O ;
Hampe, C ;
Patenge, N ;
Vaupel, K ;
Yamamoto, A ;
Dichgans, M ;
Brice, A ;
Wanker, EE ;
Kahle, PJ ;
Grasser, T .
FEBS LETTERS, 2005, 579 (18) :3913-3919
[7]   The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates [J].
Gu, WJ ;
Corti, O ;
Araujo, F ;
Hampe, C ;
Jacquier, S ;
Lücking, CB ;
Abbas, N ;
Duyckaerts, C ;
Rooney, T ;
Pradier, L ;
Ruberg, M ;
Brice, A .
NEUROBIOLOGY OF DISEASE, 2003, 14 (03) :357-364
[8]   Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity [J].
Hampe, Cornelia ;
Ardila-Osorio, Hector ;
Fournier, Margot ;
Brice, Alexis ;
Corti, Olga .
HUMAN MOLECULAR GENETICS, 2006, 15 (13) :2059-2075
[9]   Distribution, type, and origin of Parkin mutations:: Review and case studies [J].
Hedrich, K ;
Eskelson, C ;
Wilmot, B ;
Marder, K ;
Harris, J ;
Garrels, J ;
Meija-Santana, H ;
Vieregge, P ;
Jacobs, H ;
Bressman, SB ;
Lang, AE ;
Kann, M ;
Abbruzzese, G ;
Martinelli, P ;
Schwinger, E ;
Ozelius, LJ ;
Pramstaller, PP ;
Klein, C ;
Kramer, P .
MOVEMENT DISORDERS, 2004, 19 (10) :1146-1157
[10]   Pathogenic mutations inactivate parkin by distinct mechanisms [J].
Henn, IH ;
Gostner, JM ;
Lackner, P ;
Tatzelt, J ;
Winklhofer, KF .
JOURNAL OF NEUROCHEMISTRY, 2005, 92 (01) :114-122